Yu Megan, Tsai Sheng-Feng, Kuo Yu-Min
Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
Institute of Basic Medical Sciences, National Cheng Kung University, Tainan 70101, Taiwan.
Int J Mol Sci. 2017 Jun 13;18(6):1260. doi: 10.3390/ijms18061260.
Although many cardiovascular (CVD) medications, such as antithrombotics, statins, and antihypertensives, have been identified to treat atherosclerosis, at most, many of these therapeutic agents only delay its progression. A growing body of evidence suggests physical exercise could be implemented as a non-pharmacologic treatment due to its pro-metabolic, multisystemic, and anti-inflammatory benefits. Specifically, it has been discovered that certain anti-inflammatory peptides, metabolites, and RNA species (collectively termed "exerkines") are released in response to exercise that could facilitate these benefits and could serve as potential therapeutic targets for atherosclerosis. However, much of the relationship between exercise and these exerkines remains unanswered, and there are several challenges in the discovery and validation of these exerkines. This review primarily highlights major anti-inflammatory exerkines that could serve as potential therapeutic targets for atherosclerosis. To provide some context and comparison for the therapeutic potential of exerkines, the anti-inflammatory, multisystemic benefits of exercise, the basic mechanisms of atherosclerosis, and the limited efficacies of current anti-inflammatory therapeutics for atherosclerosis are briefly summarized. Finally, key challenges and future directions for exploiting these exerkines in the treatment of atherosclerosis are discussed.
尽管许多心血管疾病(CVD)药物,如抗血栓药、他汀类药物和抗高血压药,已被确定用于治疗动脉粥样硬化,但这些治疗药物大多最多只能延缓其进展。越来越多的证据表明,体育锻炼因其促进新陈代谢、多系统和抗炎的益处,可作为一种非药物治疗方法。具体而言,已发现某些抗炎肽、代谢物和RNA种类(统称为“运动因子”)会因运动而释放,这些运动因子可促进这些益处,并可能成为动脉粥样硬化的潜在治疗靶点。然而,运动与这些运动因子之间的许多关系仍未得到解答,并且在这些运动因子的发现和验证方面存在若干挑战。本综述主要强调了可作为动脉粥样硬化潜在治疗靶点的主要抗炎运动因子。为了对运动因子的治疗潜力提供一些背景和比较,简要总结了运动的抗炎、多系统益处、动脉粥样硬化的基本机制以及当前抗炎疗法对动脉粥样硬化的有限疗效。最后,讨论了在动脉粥样硬化治疗中利用这些运动因子的关键挑战和未来方向。